In-situ gelling controlled release injection of rivastigmine to treat Alzheimers disease
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: SAIF, Alasoul (King abdulaziz university, Saudi Arabia)
- Co-author(s): Rawan othman Almadfaa: pharmacy, king abdulaziz university, jeddah, Saudi Arabia
Alasoul Saif: pharmacy, king abdulaziz university, jeddah,Saudi Arabia
Hatoun labban:pharmacy, king abdulaziz university, jeddah,Saudi Arabia
Alzheimer is a neurodegenerative disease that is characterized by deterioration of cognitive & memory functions. Rivastigmine (RIV) is one of the most common drugs available for the treatment. The main challenge for its use is the frequent dosing and compliance to medications. As a result, Alzheimer's patients stop taking rivastigmine.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.